alexa Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice.
Diabetes & Endocrinology

Diabetes & Endocrinology

Journal of Diabetes & Metabolism

Author(s): Nichols GA, Conner C, Brown JB

Abstract Share this page

Abstract OBJECTIVE: To document the extent to which drug naïve patients with diabetes continued newly initiated metformin monotherapy, and who subsequently experienced primary failure or therapeutic success. RESEARCH DESIGN AND METHODS: Using an observational longitudinal cohort design, we identified all 3116 type 2 diabetes patients who initiated metformin monotherapy as their first-ever anti-hyperglycemic drug in 2004-2006. We defined initial nonadherence as having occurred in the first 6 months if a patient (1) received only a single metformin dispense, (2) received less than a 90 day supply, or (3) switched to a second anti-hyperglycemic agent. Among those patients who continued metformin monotherapy for at least 6 months, we determined the proportion attaining A1C < 7\% by examining A1Cs recorded prior to adding a second anti-hyperglycemic agent or December 31, 2008, whichever occurred first. We identified factors associated with achieving A1C < 7\% with logistic regression. RESULTS: Initial nonadherence occurred in 518 (16.6\%) of the 3116 patients studied. Of those who continued metformin for at least 6 months, a majority (71.7\% overall) achieved an A1C < 7\%, even when pre-metformin A1C was high (59.6\% among those with A1C > 9\%). Initiating metformin within 3 months of diagnosis increased the probability of success nearly three-fold compared to initiating after 12-23 months (OR 2.85, 95\% CI 2.04-3.98). Independent of duration, lower A1C at initiation increased the probability of success. CONCLUSIONS: Initiating metformin immediately at diagnosis and while A1C is still low substantially increases the probability of attaining glycemic success. Our findings support the current guidelines recommending metformin therapy as soon as type 2 diabetes is diagnosed. This study was limited by its observational design, the inability to assess reasons for metformin nonadherence, and the highly automated study setting. This article was published in Curr Med Res Opin and referenced in Journal of Diabetes & Metabolism

Relevant Expert PPTs

Relevant Speaker PPTs

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords